{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:13:03Z","timestamp":1792818783587,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2377-9-62","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T20:43:41Z","timestamp":1261169021000},"source":"Crossref","is-referenced-by-count":136,"title":["Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators"],"prefix":"10.1186","volume":"9","author":[{"given":"Samuel","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,18]]},"reference":[{"key":"276_CR1","unstructured":"Frank S, Marshall F, Plumb S, Oakes D, Shoulson I, Kieburtz K, the CARE-HD Investigators of the Huntington Study Group: Functional decline due to chorea in Huntington's disease. Neurology. 2004, 56 (suppl 3):"},{"key":"276_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"ML Verhagen","year":"2002","unstructured":"Verhagen ML, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase T: Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002, 59: 694-699.","journal-title":"Neurology"},{"key":"276_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","volume":"5","author":"OR Adam","year":"2008","unstructured":"Adam OR, Jankovic J: Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008, 5: 181-197. 10.1016\/j.nurt.2008.01.008.","journal-title":"Neurotherapeutics"},{"key":"276_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/mds.21971","volume":"23","author":"W Phillips","year":"2008","unstructured":"Phillips W, Shannon KM, Barker RA: The current clinical management of Huntington's disease. Mov Disord. 2008, 23: 1491-1504. 10.1002\/mds.21971.","journal-title":"Mov Disord"},{"key":"276_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","volume":"21","author":"E Roze","year":"2008","unstructured":"Roze E, Saudou F, Caboche J: Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol. 2008, 21: 497-503. 10.1097\/WCO.0b013e328304b692.","journal-title":"Curr Opin Neurol"},{"key":"276_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997, 48: 358-362.","journal-title":"Neurology"},{"key":"276_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007, 22: 193-197. 10.1002\/mds.21222.","journal-title":"Mov Disord"},{"key":"276_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","volume":"25","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Tintner R, Thomas M, Jankovic J: Tetrabenazine Treatment for Huntington's Disease-Associated Chorea. Clinical Neuropharmacology. 2002, 25: 300-302. 10.1097\/00002826-200211000-00003.","journal-title":"Clinical Neuropharmacology"},{"key":"276_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006, 66: 366-372. 10.1212\/01.wnl.0000198586.85250.13.","journal-title":"Neurology"},{"key":"276_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","volume":"31","author":"A Fasano","year":"2008","unstructured":"Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR: The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008, 31: 313-318. 10.1097\/WNF.0b013e318166da60.","journal-title":"Clin Neuropharmacol"},{"key":"276_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1073\/pnas.80.2.584","volume":"80","author":"D Scherman","year":"1983","unstructured":"Scherman D, Jaudon P, Henry JP: Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci USA. 1983, 80: 584-588. 10.1073\/pnas.80.2.584.","journal-title":"Proc Natl Acad Sci USA"},{"key":"276_CR12","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/0006-2952(83)90388-X","volume":"32","author":"SP Bagchi","year":"1983","unstructured":"Bagchi SP: Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol. 1983, 32: 2851-2856. 10.1016\/0006-2952(83)90388-X.","journal-title":"Biochem Pharmacol"},{"key":"276_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0014-2999(84)90563-6","volume":"102","author":"DJ Pettibone","year":"1984","unstructured":"Pettibone DJ, Pflueger AB, Totaro JA: Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol. 1984, 102: 431-436. 10.1016\/0014-2999(84)90563-6.","journal-title":"Eur J Pharmacol"},{"key":"276_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/jps.2600760610","volume":"76","author":"R Mehvar","year":"1987","unstructured":"Mehvar R, Jamali F: Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci. 1987, 76: 461-465. 10.1002\/jps.2600760610.","journal-title":"J Pharm Sci"},{"key":"276_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0006-8993(95)00674-F","volume":"692","author":"F Thibaut","year":"1995","unstructured":"Thibaut F, Faucheux BA, Marquez J, Villares J, Menard JF, Agid Y, Hirsch EC: Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res. 1995, 692: 233-243. 10.1016\/0006-8993(95)00674-F.","journal-title":"Brain Res"},{"key":"276_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mds.21161","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007, 22: 10-13. 10.1002\/mds.21161.","journal-title":"Mov Disord"},{"key":"276_CR17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0026-895X(25)15021-9","volume":"25","author":"D Scherman","year":"1984","unstructured":"Scherman D, Henry JP: Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol Pharmacol. 1984, 25: 113-122.","journal-title":"Mol Pharmacol"},{"key":"276_CR18","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"RM Bonelli","year":"2006","unstructured":"Bonelli RM, Wenning GK: Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006, 12: 2701-2720. 10.2174\/138161206777698693.","journal-title":"Curr Pharm Des"},{"key":"276_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group: Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996, 11: 136-142. 10.1002\/mds.870110204.","journal-title":"Mov Disord"},{"key":"276_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry. 1989, 154: 672-676. 10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"key":"276_CR21","first-page":"153","volume-title":"Recent development in Parkinson's disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RL, Members of the UPDRS Developmental Committee: Unified Parkinson's Disease Rating Scale. Recent development in Parkinson's disease. Edited by: Fahn S, Marsden CD, Calne DB, Goldstein M. 1987, Florham Park, NJ: Macmillan Healthcare Information, 2: 153-163."},{"key":"276_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23: 56-62. 10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"276_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/01.WNF.0000228369.25593.35","volume":"29","author":"C Kenney","year":"2006","unstructured":"Kenney C, Hunter C, Mejia N, Jankovic J: Is history of depression a contraindication to treatment with tetrabenazine?. Clin Neuropharmacol. 2006, 29: 259-264. 10.1097\/01.WNF.0000228369.25593.35.","journal-title":"Clin Neuropharmacol"},{"key":"276_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/jnnp.67.4.550","volume":"67","author":"W Schreiber","year":"1999","unstructured":"Schreiber W, Krieg JC, Eichhorn T: Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition. J Neurol Neurosurg Psychiatry. 1999, 67: 550-10.1136\/jnnp.67.4.550.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"276_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/jmg.30.4.293","volume":"30","author":"ML Di","year":"1993","unstructured":"Di ML, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM: Suicide risk in Huntington's disease. J Med Genet. 1993, 30: 293-295. 10.1136\/jmg.30.4.293.","journal-title":"J Med Genet"},{"key":"276_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ajmg.1320240211","volume":"24","author":"LA Farrer","year":"1986","unstructured":"Farrer LA: Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986, 24: 305-311. 10.1002\/ajmg.1320240211.","journal-title":"Am J Med Genet"},{"key":"276_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1176\/appi.ajp.162.4.725","volume":"162","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, Hoth KF, Nehl C, Stierman L: Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005, 162: 725-731. 10.1176\/appi.ajp.162.4.725.","journal-title":"Am J Psychiatry"},{"key":"276_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","volume":"31","author":"S Frank","year":"2008","unstructured":"Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J: A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008, 31: 127-133. 10.1097\/WNF.0b013e3180ca77ea.","journal-title":"Clin Neuropharmacol"},{"key":"276_CR29","first-page":"9","volume":"5","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Mejia N, Jankovic J: Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol. 2007, 5: 9-13.","journal-title":"J Ped Neurol"},{"key":"276_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mds.870100116","volume":"10","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Ashizawa T: Tourettism associated with Huntington's disease. Mov Disord. 1995, 10: 103-105. 10.1002\/mds.870100116.","journal-title":"Mov Disord"},{"key":"276_CR31","doi-asserted-by":"crossref","unstructured":"Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology. 1998, 50: 1366-1373.","DOI":"10.1212\/WNL.50.5.1366"},{"key":"276_CR32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","volume":"57","author":"Huntington Study Group","year":"2001","unstructured":"Huntington Study Group: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001, 57: 397-404.","journal-title":"Neurology"},{"key":"276_CR33","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","volume":"27","author":"TS Tang","year":"2007","unstructured":"Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci. 2007, 27: 7899-7910. 10.1523\/JNEUROSCI.1396-07.2007.","journal-title":"J Neurosci"}],"updated-by":[{"DOI":"10.1186\/1471-2377-11-18","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T00:00:00Z","timestamp":1296777600000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-9-62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-9-62\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-9-62","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T22:35:13Z","timestamp":1739486113000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-9-62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-9-62","relation":{"correction":[{"id-type":"doi","id":"10.1186\/1471-2377-11-18","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"article-number":"62"}}